PT  - JOURNAL ARTICLE
AU  - Stehlik, Paulina
AU  - Alcorn, Kylie
AU  - Jones, Anna
AU  - Schlebusch, Sanmarié
AU  - Wattiaux, Andre
AU  - Henry, David
TI  - Repeat testing for SARS-COV-2: Persistence of viral RNA is common, and clearance is slower in older age groups
AID  - 10.1101/2020.08.27.20183483
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.27.20183483
4099  - http://medrxiv.org/content/early/2020/11/30/2020.08.27.20183483.short
4100  - http://medrxiv.org/content/early/2020/11/30/2020.08.27.20183483.full
AB  - OBJECTIVE The Novel Coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suppression program has been relatively successful in Queensland, Australia. Initially, it involved extensive community testing and repeat sampling of positive individuals for release from isolation. This enabled study of several characteristics, including persistence of detectable virus and how apparent viral clearance rates varied by age and sex.DESIGN We conducted an exploratory analysis of Queensland Pathology SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) test results. Kaplan Meier analyses were used to estimate median time to apparent viral clearance, and Cox regression to explore the effects of sex and age.SETTING AND PARTICIPANTS Individuals tested for presence of SARS-CoV-2 in the upper respiratory tract between January 19 and June 4, 2020.OUTCOME MEASURES Presence of viral RNA detected by RT-PCR.RESULTS We analysed 97,476 individuals. Median age was 41y (range <1-105y), and 57.2% (95% CI 57.2, 57.2) were female. In total, 958 (0.98%; 95% CI 0.92,1.05) tested positive for SARS-CoV-2. Positivity rates were lower in regional areas than cities, in females (OR 0.80, 95% CI 0.70, 0.91), and in those aged 16y and below (p<0.01, test for trend).Of the 958 positive individuals, 243 had two or more (maximum 17) additional tests, and 92% (95% CI 88.1, 95.2) remained positive after 10 days (maximum 72 days) after the initial result.Median time to apparent viral clearance was longer in those 65y and over compared to those under 65y (29 v 43 days, HR 1.85; 95% CI 1.17, 2.90), and was unaffected by sex (HR 0.93; 95% CI 0.66, 1.30).CONCLUSIONS Females and those 16y and under were less likely to test positive for SARS-CoV-2. Detectable RNA may persist for long periods, negating the value of repeat testing for declaring individuals free of infection. Viral clearance rates appear lower in those over 65y of age compared with younger individuals.“The known”- Early in the COVID-19 pandemic, 2 negative RT-PCR swabs were used to achieve negative status in infected individuals- There are few published data on the patterns of results seen with repeat testing.“The new”- We analysed data from a large cohort of people tested for viral RNA in Queensland, Australia.- We found that females and those 16 y and under were less likely to test positive.- Viral RNA was detectable for up to 72 days, with >90% testing positive for more than 10 days.- Viral clearance was slower in those over the age of 65.“The implications”- Our findings support that there is likely to be little value in repeat RT-PCR testing to declare individuals free from infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Gold Coast Health Human Research Ethics Committee (LNR/2020/QGC/63045) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data not available due to privacy; analysis code, description of data structure available at our OSF webpage. https://osf.io/habvk/